Coca-Cola Consolidated, Inc.
COKE
$206.39
-3.71%
Coca-Cola Consolidated, Inc. is the largest independent bottler of Coca-Cola products in the United States, manufacturing, marketing, and distributing a broad portfolio of sparkling and still nonalcoholic beverages — including Coca-Cola trademark brands, energy drinks, bottled water, ready-to-drink tea and coffee, juices, and sports drinks — across a multi-state territory. Unlike The Coca-Cola Company, which owns the concentrate and brand IP, COKE is a capital-intensive franchise bottler whose economics are driven by volume, pricing, and route-to-market efficiency, giving it a distinct operational identity within the Consumer Defensive sector. The current investor narrative centers on a multi-year margin-expansion and capital-return story: management has aggressively repurchased stock (roughly $2.46 billion in Q4 2025 alone) and deleveraged the balance sheet, while steady mid-single-digit revenue growth and gross margin near 39% have supported a re-rating of the shares. Attention is now focused on whether the company can sustain operating leverage as it laps a period of unusually strong pricing, and on the sustainability of buyback-driven EPS growth as the share count shrinks and the equity base turns negative.…
COKE
Coca-Cola Consolidated, Inc.
$206.39
Investment Opinion: Should I buy COKE Today?
Rating: Hold (accumulate on pullbacks). Coca-Cola Consolidated pairs genuine, cash-backed operating leverage — net margin up to 8.84% from 7.54% and $552.9 million of trailing free cash flow — with a roughly 24% diluted share-count reduction (66.6 million vs. 87.3 million a year ago) that mechanically compounds EPS, but at $214.34 the stock trades at 19.78x trailing earnings after a 43.05% YTD run and sits just 2.6% below its 52-week high of $219.99. The view cannot be anchored to sell-side consensus because coverage is effectively absent — one analyst, no recommendation, and EPS estimates reported as zero — so the sole revenue estimate of $7.23 billion is the only external anchor, and it implies roughly 5% growth consistent with the 5.36% just delivered.
Supporting evidence is strong on cash and weak on price. Free cash flow of $552.9 million covers Q3 capex of $71.9 million and dividends of $16.6 million with wide margin, and the 15.19% payout ratio with a 0.77% yield leaves room for continued returns. Operating leverage is real: SG&A held at $500.0 million against 5.4% revenue growth lifted operating margin to 13.65% and EBITDA to $326.1 million (16.39% margin) from $252.0 million. But the valuation is no longer cheap — trailing PE of 19.78x versus 15.51x in Q3 2025 and 10.13x at year-end 2022, EV/EBITDA of 15.40x, PEG of 1.87, and price-to-FCF of 12.05x — and the eye-catching 5.50x forward PE is a share-count artifact rather than an organic earnings signal. Gross margin has also slipped to 38.78% from 39.64% a year earlier, so all margin expansion now comes from below the gross line.
Three risks could invalidate the thesis: a slowdown in buybacks that removes the EPS-accretion engine, further gross-margin compression from input costs or promotional intensity, and a volume pullback in the Nonalcoholic Beverage segment that supplies $1.976 billion of the $2.076 billion total. This Hold would upgrade to Buy if the stock pulled back toward the $190–$195 zone (roughly 17x–18x trailing earnings) while gross margin stabilized above 39%, or if a second analyst initiated coverage with a constructive target; it would downgrade to Sell if gross margin fell below 38% or if quarterly buybacks decelerated sharply while revenue growth slipped under 4%. Verdict: fairly valued to modestly rich relative to its own multi-year history, with the premium defensible only if capital returns persist at scale.
Sign up to view all
COKE 12-Month Price Forecast
The forward view is balanced: the business is generating real cash and real operating leverage, but the market has already paid for much of it with a trailing multiple that has nearly doubled since 2022. The 5.50x forward PE is not a genuine bargain signal — it reflects a collapsing share count from roughly $2.46 billion of Q4 2025 buybacks — so the durability of repurchases, not organic profit acceleration, is the swing factor. Analyst sentiment offers no guidepost given one analyst, no recommendation, and zeroed EPS estimates, which cuts both ways: no downgrade risk from consensus, but also no institutional bid to support a reset. I would upgrade to bullish if gross margin stabilized above 39.5% while buybacks continued and the stock broke $219.99, and downgrade to bearish if gross margin fell below 38% or repurchase cadence slowed materially alongside sub-4% revenue growth.
Wall Street consensus
Insufficient analyst coverage available. Only one analyst covers COKE, with no consensus recommendation (reported as "none") and no published EPS estimates — the estimated EPS average, low, and high are all zero, leaving no basis for a consensus target price or implied upside calculation. The sole revenue estimate of $7.23 billion provides a rough full-year top-line anchor but no directional signal on valuation. This thin coverage is typical of a mid-cap bottler with a dual-class share structure and limited institutional float, and it means price discovery relies more on retail and index flows than on sell-side research.\n\nThe institutional ratings history reinforces the coverage gap: the only recorded actions are seven Citigroup "Neutral" ratings stretching from 2012 to 2016, with no upgrades, downgrades, or initiations since — a decade-long research desert. Without a target range, there is no way to gauge whether the sell-side sees the high end of the stock's move as justified by margin expansion and buybacks or the low end as vulnerable to volume pressure and input costs. Investors should treat the absence of coverage as a risk factor: it implies higher volatility, less efficient price discovery, and greater sensitivity to any single analyst initiation, while also creating the potential for a positive surprise if broader coverage begins as the company's market cap ($13.3 billion) and liquidity grow.
Drowning in data?
Find the real signal!
Bulls vs Bears: COKE Investment Factors
The bull case currently has stronger evidence: COKE pairs genuine operating leverage (net margin up to 8.84% from 7.54%) and $552.9 million of trailing FCF with a 24% share-count reduction that mechanically multiplies EPS, all wrapped in a low-beta 0.61 package that has beaten SPY by 20.47 points over a year. The bear case rests less on business deterioration than on price — a trailing PE that has nearly doubled from 10.13x at year-end 2022 to 19.78x, a gross margin drifting down from ~40%, and a balance sheet with negative equity after $2.46 billion of Q4 2025 buybacks. The single most important tension is whether buyback-driven EPS accretion can continue as the share count shrinks and the equity base turns negative, or whether the forward PE of 5.50x is a distortion that unwinds once repurchases slow. If repurchases persist at scale, the re-rating is defensible; if they decelerate, the stock is a 19.78x trailing-earnings bottler growing revenue at 5.36% with no analyst coverage to cushion the reset.
Bullish
- Powerful momentum with market leadership: COKE is up 32.74% over the trailing year and 43.05% YTD versus SPY's 12.27% and 10.62%, a relative strength advantage of +20.47 and +32.43 percentage points respectively. The stock gained 7.17% in the past month while SPY fell 2.26%, a bullish divergence showing COKE rallying against a weak tape. At $214.34 it sits at roughly 92.7% of its 52-week range ($142.83–$219.99), confirming a sustained uptrend rather than a beta-driven bounce.
- Buyback-driven EPS accretion is dramatic: Diluted shares fell to 66.6 million in Q3 2026 from 87.3 million a year earlier, a roughly 24% reduction, after management repurchased about $2.46 billion of stock in Q4 2025 alone. This mechanical shrink is the main driver behind the trailing PE of 19.78x versus a forward PE of just 5.50x, and it explains why EPS rose to $2.64 from $1.64 despite only 5.36% revenue growth.
- Operating leverage expanding margins: Q3 2026 SG&A was essentially flat at $500.0 million against 5.4% revenue growth, lifting operating margin to 13.65% and net margin to 8.84% from 7.54% a year earlier. EBITDA rose to $326.1 million (16.39% margin) from $252.0 million, demonstrating that cost discipline is converting modest top-line gains into disproportionate profit growth.
- Robust free cash flow covers returns: Trailing twelve-month free cash flow is $552.9 million, with quarterly FCF of $172.2 million in Q3 2026 comfortably covering $71.9 million of capex and $16.6 million of dividends. The current ratio of 1.26 and ROA of 12.41% show the business generates ample internal cash to fund both reinvestment and shareholder returns despite negative book equity.
Bearish
- Valuation re-rated to multi-year highs: The trailing PE of 19.78x compares with 15.51x in Q3 2025, 12.96x in Q2 2025, and 10.13x at year-end 2022 — a clear multi-year re-rating. With revenue growth decelerating to 5.36% and a PEG of 1.87, further multiple expansion looks harder to justify than earnings-driven upside, and the 43.05% YTD gain means much good news is already priced in.
- Gross margin compressing from peak: Gross margin fell to 38.78% in Q3 2026 from 39.64% a year earlier, and the trailing figure of 39.74% masks a downward drift from roughly 40% in mid-2025. The margin expansion story is being carried entirely below the gross line by SG&A discipline, leaving little buffer if input costs or promotional intensity rise.
- Negative equity limits financial flexibility: Aggressive buybacks have driven shareholders' equity negative, producing a debt-to-equity ratio of -3.93 and price-to-book of -15.26. While these are capital-structure artifacts rather than distress, they mean traditional leverage metrics are uninformative and the balance sheet has little room for a large debt-funded acquisition or a downturn.
- Near-zero analyst coverage: Only one analyst covers COKE, with no consensus recommendation and EPS estimates all reported as zero, and the sole recorded ratings history is seven Citigroup Neutrals from 2012–2016 with nothing since. This research desert implies less efficient price discovery, higher volatility, and outsized sensitivity to any single initiation or downgrade.
COKE Technical Analysis
COKE is in a sustained, powerful uptrend: the stock is up 32.74% over the trailing year and 43.05% year-to-date, dramatically outpacing the S&P 500's 12.27% and 10.62% respective gains. At a current price of $214.34, the shares sit at roughly 92.7% of the 52-week range (low $142.83, high $219.99), just below the upper boundary — a positioning that signals strong momentum but also leaves limited near-term headroom before resistance and raises the risk of overextension. The relative strength versus SPY of +20.47 percentage points over one year confirms this is a genuine leadership name rather than a beta-driven rally.\n\nShort-term momentum is accelerating rather than fading. The stock gained 7.17% over the past month and 13.34% over three months, and the one-month relative strength of +9.43 points versus a -2.26% decline in SPY shows COKE rallying while the broad market pulled back — a bullish divergence. The most recent session added 3.55% on a close of $214.34, pushing the price to a fresh local high after a consolidation between roughly $203 and $210 in late October. With the 6-month gain of 25.88% and YTD gain of 43.05% all pointing the same direction, there is no bearish divergence in the trend structure; the main caution is that the pace of gains has steepened, which historically precedes short-term mean reversion.\n\nKey technical levels are well defined. Resistance sits at the 52-week high of $219.99 — a breakout above that level would confirm the uptrend and likely trigger momentum-driven buying, while the $203–$204 area (the late-October swing lows) is the first support shelf. Deeper support rests at the 52-week low of $142.83, roughly 33% below current levels, and the maximum drawdown over the past year of -24.66% shows the stock can correct sharply when momentum breaks. With a beta of just 0.61, COKE is roughly 40% less volatile than the market, which supports larger position sizing for risk-adjusted return but also means the stock will likely lag in a broad risk-on melt-up; the short ratio of 5.23 days-to-cover indicates moderate short interest that could add fuel to a breakout.
Beta
—
—
Max Drawdown
-24.7%
Largest decline past year
52-Week Range
—
Price range past year
Annual Return
+29.4%
Cumulative gain past year
| Period | COKE Return | S&P 500 |
|---|---|---|
| 1m | -1.9% | -3.0% |
| 3m | +9.4% | -3.6% |
| 6m | +17.1% | -0.2% |
| 1y | +29.4% | +10.1% |
| ytd | +37.7% | +8.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
COKE Fundamental Analysis
Revenue is growing steadily but at a moderating pace. Q3 2026 revenue came in at $1.99 billion, up 5.36% year-over-year from $1.888 billion in Q3 2025, following Q2 2026 revenue of $2.052 billion and Q1 2026 revenue of $1.847 billion — a sequential pattern consistent with normal beverage seasonality rather than deceleration. The Nonalcoholic Beverage segment dominates the mix at $1.976 billion of the $2.076 billion total, with the small "All Other" segment contributing just $99.6 million, so the investment case rises and falls almost entirely on carbonated and still beverage volume and pricing. The mid-single-digit growth rate implies the company is capturing price/mix rather than relying on volume, which is a higher-quality but less explosive growth profile.\n\nProfitability is solid and improving. Q3 2026 net income was $175.9 million on a 38.78% gross margin and 13.65% operating margin, with net margin of 8.84% — up from 7.54% net margin in Q3 2025 despite a slightly lower gross margin (39.64% a year ago). The margin expansion is being driven below the gross line: SG&A of $500.0 million was essentially flat year-over-year against 5.4% revenue growth, producing operating leverage, while EBITDA rose to $326.1 million (16.39% EBITDA margin) from $252.0 million a year earlier. The trailing valuation data shows a 39.74% gross margin and 13.15% operating margin, consistent with a mature, efficiently run bottler; the key watch item is that gross margin has compressed modestly from ~40% in mid-2025, suggesting input-cost or mix pressure that operating discipline is currently offsetting.\n\nThe balance sheet is the most unusual feature of this story. Aggressive buybacks have driven shareholders' equity negative, producing a debt-to-equity ratio of -3.93 and a price-to-book of -15.26 — these figures are artifacts of capital structure, not distress, but they do mean traditional leverage metrics are uninformative. Liquidity is adequate with a current ratio of 1.26, and free cash flow remains robust: $552.9 million trailing twelve months, with quarterly FCF of $172.2 million in Q3 2026, $131.1 million in Q2, and $142.2 million in Q1, comfortably covering capital expenditures of $71.9 million and dividends of $16.6 million in the latest quarter. ROA of 12.41% is healthy, though the reported ROE of -77.13% is meaningless given negative equity; the company is generating enough cash internally to fund capex and returns, but the buyback program has consumed balance-sheet flexibility, leaving little room for a large debt-funded acquisition or a downturn.
Quarterly Revenue
$2.0B
2026-10
Revenue YoY Growth
+5.4%
YoY Comparison
Gross Margin
38.8%
Latest Quarter
Free Cash Flow
$552856000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is COKE Overvalued?
Because net income is positive ($175.9 million in Q3 2026), the PE ratio is the appropriate primary metric. COKE trades at a trailing PE of 19.78x versus a forward PE of just 5.50x — an extraordinarily wide gap that implies the market expects earnings to multiply several-fold, a distortion likely driven by the collapsing share count (66.6 million diluted shares versus 87.3 million a year ago) and buyback-driven EPS mechanics rather than organic profit growth. The PEG ratio of 1.87 and EV/EBITDA of 15.40x suggest the stock is not cheap on cash-flow-based measures even if the headline trailing PE looks moderate.\n\nRelative to the broader Beverages - Non-Alcoholic industry, COKE screens as a mixed case. Its PS ratio of 1.56x and EV/Sales of 2.13x are low in absolute terms for a Consumer Defensive name, reflecting the bottler's lower-margin, capital-intensive model versus brand owners like The Coca-Cola Company, which typically command PS multiples several times higher. However, the EV/EBITDA of 15.40x and price-to-free-cash-flow of 12.05x are closer to fair value for a mature bottler, and the 39.74% gross margin and 7.89% net margin are respectable but structurally below concentrate-owner economics. The premium embedded in the forward PE gap is best read as a bet on continued buyback-driven EPS accretion rather than a durable earnings re-rating.\n\nOn its own history, COKE is trading near the upper end of its valuation band. The trailing PE of 19.78x compares with 15.51x in Q3 2025, 12.96x in Q2 2025, and 10.13x at year-end 2022 — a clear multi-year re-rating. The PS ratio of 1.56x, however, is well below the 6.43x reported in the Q3 2026 historical ratios snapshot, a discrepancy that reflects the share-count and equity-base distortions from buybacks rather than a genuine valuation collapse. The stock's YTD gain of 43.05% against 10.62% for SPY means the market has already priced in a lot of good news; at 19.78x trailing earnings with decelerating revenue growth, further multiple expansion looks harder to justify than earnings-driven upside.
PE
19.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~29x
vs. Industry Avg
31.5x
Industry PE ~31.5x*
EV/EBITDA
15.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the sustainability of a capital-return program that has already consumed the balance sheet. Buybacks of roughly $2.46 billion in Q4 2025 drove shareholders' equity negative, producing a debt-to-equity ratio of -3.93 and a price-to-book of -15.26, which renders traditional leverage metrics uninformative and leaves little capacity for a debt-funded acquisition or a demand downturn. Gross margin slipped to 38.78% in Q3 2026 from 39.64% a year earlier, so the entire margin story now depends on SG&A discipline — flat at $500.0 million against 5.36% revenue growth — and would crack if input costs or promotional spending rose. Revenue is also highly concentrated: the Nonalcoholic Beverage segment contributed $1.976 billion of the $2.076 billion total, tying the investment case almost entirely to carbonated and still beverage volume and pricing in a single franchise system.
Market and competitive risks are dominated by valuation compression. The trailing PE of 19.78x has nearly doubled from 10.13x at year-end 2022 and sits well above the 15.51x of Q3 2025, while EV/EBITDA of 15.40x and a PEG of 1.87 offer no margin of safety for a bottler growing revenue at 5.36%. As a franchise bottler, COKE has limited pricing power independent of The Coca-Cola Company's concentrate pricing and brand decisions, and its 39.74% gross margin is structurally below concentrate-owner economics. With a beta of just 0.61 the stock is only partially insulated from macro shocks, and the near-total absence of sell-side coverage — one analyst, no consensus, no EPS estimates — means any single initiation or downgrade could move the shares disproportionately. No recent news flow is available to offset these structural concerns.
The worst-case scenario is a buyback slowdown coinciding with gross-margin compression and a volume pullback, forcing the market to value COKE as a mid-single-digit-growth bottler rather than an EPS-compounding machine. In that chain of events, the trailing multiple could retrace toward the 12.96x–15.51x range seen in 2025, and the stock could revisit its 52-week low of $142.83 — roughly 33% below the current $214.34. The past year's max drawdown of -24.66% is a realistic guide to an ordinary correction, implying a decline to roughly $161, while a full de-rating to the 52-week low would cost an investor about -33%. With no analyst bear-case target available due to the coverage gap, the 52-week low and the historical drawdown are the most reliable downside anchors.
FAQ
Ranked by severity: first, capital-return dependence — roughly $2.46 billion of Q4 2025 buybacks drove shareholders' equity negative (debt-to-equity of -3.93, price-to-book of -15.26), so any slowdown in repurchases removes the main EPS driver behind the 5.50x forward PE. Second, margin compression — gross margin fell to 38.78% in Q3 2026 from 39.64% a year earlier, leaving all margin expansion dependent on flat SG&A of $500.0 million, which would crack if aluminum, freight, or promotional costs rise. Third, revenue concentration — the Nonalcoholic Beverage segment supplies $1.976 billion of the $2.076 billion total, tying the thesis to a single franchise system where pricing power is constrained by The Coca-Cola Company's concentrate decisions. Fourth, coverage and liquidity risk — one analyst, no consensus recommendation, and no EPS estimates mean inefficient price discovery and outsized sensitivity to any single initiation or downgrade, amplified by a 5.23-day short ratio and a -24.66% max drawdown over the past year.
The base case carries 50% probability with a $200–$225 range, assuming revenue growth of roughly 4%–6% near the $7.23 billion sole analyst estimate, gross margin holding in the 38.5%–39.5% band, and buybacks continuing at a moderated pace that keeps the multiple pinned near 19x–20x trailing earnings. The bull case at 25% probability targets $235–$250, requiring repurchases to shrink diluted shares below 60 million, gross margin to recover above 39.5% on easing input costs, and a decisive break above the $219.99 52-week high. The bear case at 25% probability targets $143–$165, driven by a buyback slowdown coinciding with gross-margin compression and volume weakness, retracing the multiple toward the 12.96x–15.51x range seen in 2025 and revisiting the 52-week low of $142.83. The base case is most likely because the operating leverage and cash generation are already demonstrated, while the re-rating has already occurred — leaving consolidation as the path of least resistance absent a new catalyst.
COKE screens as fairly valued to modestly rich relative to its own history. The trailing PE of 19.78x compares with 15.51x in Q3 2025, 12.96x in Q2 2025, and 10.13x at year-end 2022 — a clear multi-year re-rating that has already captured much of the margin and buyback story. The headline forward PE of 5.50x is not a genuine bargain signal; it is an artifact of a collapsing share count (66.6 million diluted vs. 87.3 million a year ago) rather than an organic earnings inflection. On cash-flow measures the stock looks closer to fair: EV/EBITDA of 15.40x, price-to-free-cash-flow of 12.05x, and a PEG of 1.87. Absolute multiples are low — PS of 1.56x and EV/Sales of 2.13x — but that reflects the capital-intensive bottler model with a 39.74% gross margin, structurally below concentrate owners like The Coca-Cola Company. The market is pricing in continued buyback-driven EPS accretion; if repurchases slow, the premium is vulnerable.
The risk/reward is balanced rather than compelling at $214.34. On the positive side, COKE has delivered 32.74% over the trailing year and 43.05% YTD versus SPY's 12.27% and 10.62%, with a beta of just 0.61, $552.9 million of trailing free cash flow, and EPS that rose to $2.64 from $1.64 on only 5.36% revenue growth thanks to a 24% share-count reduction. On the negative side, the stock trades at 19.78x trailing earnings — nearly double the 10.13x of year-end 2022 — sits just 2.6% below its $219.99 52-week high, and carries a PEG of 1.87 with gross margin slipping to 38.78% from 39.64%. There is no analyst consensus target to anchor upside, since the sole covering analyst publishes no recommendation and zeroed EPS estimates. It is a reasonable buy for long-term, risk-aware investors on a pullback toward the $190–$195 zone (roughly 17x–18x trailing earnings), but chasing at current levels offers limited margin of safety against a -24.66% historical max drawdown.
COKE is better suited to long-term holding than short-term trading, though its momentum profile makes it viable for tactical positions with tight risk controls. The business is a mature, capital-intensive bottler with mid-single-digit revenue growth, a 0.77% dividend yield, and a 15.19% payout ratio — it is not an income vehicle, and its compounding comes from buybacks and operating leverage rather than top-line acceleration. Earnings visibility is decent but unvalidated: one analyst, no consensus recommendation, and zeroed EPS estimates mean no institutional scaffolding for price discovery, which raises volatility around catalysts. A beta of 0.61 supports larger position sizing for risk-adjusted returns, but the -24.66% max drawdown over the past year shows the stock can correct sharply when momentum breaks. A minimum holding period of 12–18 months is appropriate — long enough to capture at least one full buyback and gross-margin cycle — with entry preferably on pullbacks toward $190–$195 rather than at the current $214.34, just 2.6% below the 52-week high.

